Skip to main content
  • Book
  • © 2016

Interleukin 12: Antitumor Activity and Immunotherapeutic Potential in Oncology

  • Explores the biology of interleukin 12 and its potential in cancer therapy
  • Discusses antitumor effects identified in preclinical studies and clinical trials in cancer immunotherapy
  • Is particularly relevant for scientists working in the pharmaceutical industry and in clinical oncology
  • Includes supplementary material: sn.pub/extras

Part of the book series: SpringerBriefs in Immunology (BRIEFSIMMUN)

Buy it now

Buying options

eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

This is a preview of subscription content, log in via an institution to check for access.

Table of contents (3 chapters)

  1. Front Matter

    Pages i-vii
  2. Biology of IL-12

    • Radoslaw Zagozdzon, Witold Lasek
    Pages 1-19
  3. Antitumor Effects of IL-12 in Preclinical Studies

    • Witold Lasek, Marek Jakóbisiak
    Pages 21-41
  4. Clinical Trials with IL-12 in Cancer Immunotherapy

    • Witold Lasek, Radoslaw Zagozdzon
    Pages 43-75

About this book

This book discusses the immunotherapeutic potential of Interleukin 12 in the context of clinical oncology, as well as antitumor effects confirmed in preclinical studies and clinical trials in cancer immunotherapy. Due to its ability to activate both innate (NK cells) and adaptive (cytotoxic T lymphocytes) immunities, Interleukin 12 (IL-12) has been regarded as a promising candidate for tumor immunotherapy. However, despite the encouraging results in animal models, only very modest antitumor effects have been confirmed in early clinical trials. Recently, several clinical studies have been initiated in which IL-12 was applied as an adjuvant in cancer vaccines, in gene therapy including locoregional injections of IL-12 plasmid, and in the form of tumor-targeting immunocytokines (IL-12 fused to monoclonal antibodies).

Authors and Affiliations

  • Department of Immunology, Centre for Biostructure Research, Medical University of Warsaw, Warsaw, Poland

    Witold Lasek

  • Department of Immunology, Medical University of Warsaw, Warsaw, Poland

    Radoslaw Zagozdzon

Bibliographic Information

Buy it now

Buying options

eBook USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access